IngredientsTaka-amylase, also known as Taka-Diastase, is an enzyme preparation primarily composed of α-amylase (EC 3.2.1.1), a starch-hydrolyzing enzyme derived from the fungus Aspergillus oryzae. The enzyme is classified within the glycoside hydrolase family 13 (GH13) and is formally designated 4-α-D-glucan glucanohydrolase. Taka-amylase is one of the earliest amylases to be characterized and used commercially, and is a retaining α-amylase belonging to the GH13 subfamily 1. The name "Taka" is sometimes attributed to the Greek word meaning "best" or "excellent," and is also the first syllable of its inventor's family name. The enzyme name comes from the term "Diastase," meaning "enzyme," rendered in easier-to-pronounce German pronunciation, and "Taka," which means "best" or "excellent" in Greek and is also the first half of Dr. Takamine's name.
In scientific literature, the enzyme is frequently referred to as "Taka-amylase A" (TAA), distinguishing it as the principal α-amylase isoform produced in solid-state cultivation of A. oryzae. The parent preparation, Taka-Diastase, is a crude multi-enzyme mixture, while purified Taka-amylase A refers specifically to the single enzymatic component. Jokichi Takamine developed the world-renowned digestive agent Takadiastase, derived from culturing koji mold and wheat bran and sold commercially since the late 19th century by Parke-Davis and Sankyo corporations; Takadiastase, manufactured in large quantities at Sankyo Corporation, contains taka-amylase as its main constituent.
Takadiastase is a form of diastase which results from the growth, development, and nutrition of a distinct microscopic fungus known as Aspergillus oryzae (Koji). A. oryzae is a filamentous ascomycete fungus that has been employed in East Asian fermentation for over a thousand years. It has been used in Japan for over a thousand years to produce traditional fermented foods like sake, soy sauce, and miso. Eiji Ichishima of Tohoku University called the kōji fungus a "national fungus" (kokkin) in the journal of the Brewing Society of Japan, because of its importance not only for making the kōji for sake brewing, but also for making the kōji for miso, soy sauce, and a range of other traditional Japanese foods.
Taka-diastase is formally defined as an amylolytic enzyme formed by the action of the spores of the fungus Aspergillus oryzae on the bran of wheat; used as a digestant. The original and still-used production substrate is wheat bran, and cultivation occurs in thin, solid-state layers — a technique known as solid-state cultivation or koji fermentation. A filamentous fungus, Aspergillus oryzae, is the key organism in the production of all these traditional foods, and its solid-state cultivation (SSC) has been confirmed to be the secret for the high productivity of secretory hydrolases vital for the fermentation process.
Supplemental amylase is usually derived from microbial sources, such as Aspergillus oryzae, or less commonly from plants or animal pancreas. Supplemental amylase is typically produced through microbial fermentation, such as from Aspergillus oryzae, and is available as capsules, tablets, or blends in digestive enzyme formulas.
In the early era of its commercialization, Taka-Diastase was sold as a yellowish-white hygroscopic powder. Taka-Diastase is an enzyme preparation obtained usually as a yellowish white hygroscopic powder by growing a mold (Aspergillus oryzae) on wheat bran and used chiefly as a starch digestant. Today, the enzyme is incorporated in a wide variety of dietary supplement forms, including capsules, tablets, and multi-enzyme powder blends. Microbial amylase is favored for its vegetarian suitability and stability, making it commonly used in digestive enzyme blends found in capsules and tablets.
Taka-amylase A is also produced and sold in highly purified crystalline forms for research purposes and as a reference standard, having been the subject of intensive structural and biochemical investigation.
The enzymatic activity that defines Taka-amylase has its deepest roots in Japanese and broader East Asian fermentation culture. Analogous enzymatic activity was harnessed through traditional fermentation processes involving Aspergillus oryzae, known as koji mold, which played a central role in producing sake, soy sauce, and miso by rapidly breaking down rice starches. The word 'koji' actually refers to the solid-state fermentation involving both A. oryzae and the fermented materials that consist of rice, soybean, and wheat.
The inoculum of A. oryzae used in fermentation, known as 'koji', has been commercially produced for around 700 years. Koji is created by cultivating koji-fungus on grains, and koji starter manufacturers have selected and bred strains to improve the flavor and color of various fermented products. Aspergillus oryzae not only provides the needed enzymes for transforming raw materials into more readily digestible components but also contributes to the color, flavor, aroma, and texture of the fermented products. While these fermented foods were consumed for culinary, nutritional, and ceremonial purposes in traditional culture, the amylolytic activity of the koji mold was not identified or extracted as a discrete medicinal product until the late 19th century.
Jokichi Takamine, a Japanese chemist trained in applied chemistry at the University of Tokyo and the University of Glasgow, sought to bridge these traditions by developing a more efficient enzyme source for industrial applications. Drawing on his knowledge of koji fermentation, Takamine began experiments in the late 1880s to cultivate A. oryzae under controlled conditions, adding chemicals to accelerate enzyme production and yield a purified form superior to traditional malt diastase.
In 1894, Takamine applied for, and was granted, a US patent titled "Process of Making Diastatic Enzyme" (U.S. patent 525,823), the first patent on a microbial enzyme in the United States. Patented in 1894, it was perhaps the world's first patent on a microbial enzyme, as well as the first commercially produced microbial enzyme in the U.S. The production method involved inoculating mold spores on steamed rice or wheat bran and growing cultures in thin layers — a direct adaptation of the Japanese koji tradition to a Western pharmaceutical manufacturing context. Takamine inoculated mold spores on steamed rice or wheat bran and grew his cultures in thin layers.
Takamine continued to advocate for the use of diastase and discovered that it could be used to treat stomach problems when he himself was sick in the hospital. This experience led him to license the patent for Taka-diastase to the Detroit-based pharmaceutical company Parke, Davis & Co. He licensed his preparation to Parke–Davis and Company under the brand name Taka-diastase, and the company marketed the product as a digestive aid for the treatment of dyspepsia.
Parke, Davis & Co. quickly obtained U.S. marketing rights, positioning the product as an advanced alternative to malt extracts and pancreatin powders. At the time, digestive aids were a booming pharmaceutical market, promoted not only to treat diagnosed disease but also as "stomach strengtheners" for the general public. Taka-Diastase was marketed for conditions involving digestive insufficiency, particularly those affecting starch digestion. It was often prescribed for dyspepsia, chronic gastritis, and other ailments attributed to "weak digestion." The label describes the product's ability to convert starches into maltose and dextrins, making it a favored digestive aid in the early 20th century.
The patented production of A. oryzae Taka-diastase, a neutral α-amylase, as a medicine in 1894 marked the beginning of modern enzyme biotechnology. Taka-Diastase was also sold by the Sankyo Corporation in Japan, and the product featured prominently in popular culture; Taka-Diastase is still used as an ingredient in medicines, and was in fact mentioned long ago in Soseki Natsume's novel "I Am a Cat."
By the mid-20th century, Taka-Diastase's use waned as modern gastroenterology advanced and over-the-counter antacids and digestive enzymes diversified. The enzyme preparation remained available in Japan and in specialty markets, and the purified enzyme itself became a cornerstone of academic enzymology throughout the 20th century.
The early industrial application before its medicinal use centered on whiskey distillation. Japanese distillers used a specific mold that grew on rice fields known as koji, or Aspergillus oryzae. Known as Japan's "national fungus," A. oryzae produces an enzyme that consumes starch very quickly, then produces the sugars needed to make alcohol as a by-product. Takamine initially commercialized this activity for the American whiskey industry before redirecting it toward medicine.
Aspergillus oryzae α-amylase is a protein of Mr = 53,662 Daltons comprised of 478 amino acids, with an unusually high proportion of aromatic residues. It has one tightly bound calcium ion. The enzyme belongs to the GH13 family (also called the α-amylase superfamily), whose members share a conserved (β/α)8-barrel catalytic domain. Taka-amylase is a typical endo-type amylase, and it catalyzes the hydrolysis of α-1,4-glucosidic linkages of α-1,4-glucans.
The enzyme has one tightly bound calcium ion, and X-ray crystallography has revealed that the Ca²⁺ cation, having ligands His210, Cys164 and Glu162 main chain carbonyl oxygens, as well as the side chain carboxyl of Asp175, is an integral component of the three-dimensional structure. The calcium ion is essential for maintaining the enzyme's three-dimensional architecture and catalytic competence.
The enzyme is glycosylated; glycosylation at Asn197 is evident, and in the tetragonal crystal can be seen to include three, partially disordered sugar residues following the initial N-acetyl glucosamine (NAG).
The crude preparation known as Taka-Diastase contains additional enzymatic activities beyond α-amylase. Aspergillus oryzae is an important source of organic compounds, such as glutamic acid, and many industrial enzymes, such as glucoamylase, α-amylases, cellulase, and proteases, used for starch processing, baking, producing detergents, and brewing worldwide. Crucially, the commercial Taka-diastase mixture was the source from which a key ribonuclease was first identified: since its discovery by Sato and Egami (1957) in a commercial enzyme mixture from Aspergillus oryzae called Taka-diastase, ribonuclease (RNase) T1 [EC 3.1.27.3] has been the subject of extensive studies. RNase T1 is itself a scientifically important enzyme in molecular biology but is not the active digestive constituent of the preparation.
Aspergillus oryzae produces two α-amylases named AmyA and AmyB, where AmyB is a proteolysis derivative of AmyA. Both enzymes attain maximal activity at pH 5.6 and 50°C and produce maltose and maltotriose as major starch hydrolysis end products.
Catalysis by alpha-amylase involves the hydrolysis of the alpha-1,4 linkages in amylose with a net retention of the anomeric configuration, via a double-displacement mechanism, as originally outlined by Koshland. This double-displacement mechanism, also called a retaining mechanism, proceeds through a covalent glycosyl-enzyme intermediate and relies on two catalytic residues acting as a nucleophile and an acid/base catalyst. The enzymatic acid/base and nucleophile, residues Glu230 and Asp206, respectively, are appropriately positioned for catalysis.
α-Amylases act at a random location along the starch chain and act anywhere on the substrate; they are considered the leading enzyme and are employed in starch processing industries to hydrolyze polysaccharides. As an endo-acting enzyme, Taka-amylase cleaves starch chains internally rather than from the chain ends, generating a mixture of short oligosaccharides, maltose (a disaccharide of glucose), and maltotriose as principal products. It functions by breaking down starch into maltose and other simpler sugars, with one unit of activity defined as the amount that liberates 1 μmol of maltose per minute at pH 6.0 and 25°C using soluble starch as substrate.
The enzyme α-amylase E.C. 3.2.1.1 catalyzes hydrolysis of α-D-(1,4) glycosidic linkages in starch and related carbohydrates. At the structural level, the active site of Taka-amylase accommodates up to six sugar-ring subsites (numbered −3 to +3), and the enzyme undergoes conformational engagement with its polysaccharide substrate across multiple contiguous glucose residues. The hexasaccharide occupies the −3 to +3 subsites of the enzyme, consistent with the known number of subsites determined by kinetic studies.
Superposition of the Taka-amylase model on the α-amylases from Bacillus subtilis, pig pancreas, and barley shows a high degree of coincidence, particularly for the catalytic core. This structural conservation across widely different biological kingdoms (fungal, plant, animal) reflects the fundamental importance of this enzymatic reaction in carbohydrate metabolism. The structural similarity to human pancreatic α-amylase means the two enzymes share essentially identical chemistry and catalytic residues, rationalizing Taka-amylase's use as a functional substitute for endogenous human amylase in the gastrointestinal tract.
Amylase is a digestive enzyme predominantly secreted by the pancreas and salivary glands, with minimal presence in other tissues. The enzyme was first described in the early 1800s and is considered one of the earliest subjects of enzymology; initially termed diastase, it was renamed amylase in the early 20th century. The primary function of amylases is to hydrolyze glycosidic bonds in starch molecules, converting complex carbohydrates into simpler sugars.
Amylase breaks down complex carbohydrates like starches into simpler sugars, supporting carbohydrate digestion and nutrient absorption in the digestive tract. Taka-Diastase has been used as a digestive agent for supporting the function of amylase in a living body; accordingly, the pharmacological effect of Taka-Diastase is the enhancement of amylase activity. When taken orally before or with a meal, the exogenous enzyme supplementation is intended to support or substitute for endogenous salivary and pancreatic amylase activity.
The primary and best-established application of Taka-amylase/Taka-diastase as a supplement is the facilitation of dietary starch digestion. The biochemical rationale is well-supported: amylase in digestive enzyme supplements helps break down complex carbohydrates, like starches from foods such as bread or rice, into simpler sugars. This supports the body's natural digestion and may help ease digestive discomfort after high-carbohydrate meals by improving the efficiency of carbohydrate breakdown and nutrient absorption.
However, direct, large-scale randomized controlled trials specifically isolating Taka-amylase as a single agent in defined human populations are limited in the peer-reviewed literature accessible through standard databases. Most available clinical evidence on orally administered A. oryzae-derived amylase comes from multi-enzyme supplement studies rather than from trials of Taka-amylase as an isolated agent. Several clinical studies have shown the significance of enzyme supplements in improving digestion and treating digestive disorders. In one clinical study, supplementation of N-SORB® (a multi-enzyme complex) for 90 days showed improvement in gut health and gastrointestinal and metabolic functions. This and similar studies make it difficult to attribute effects solely to the amylase component.
In vitro evidence is more detailed. The effect of a digestive enzyme supplement containing amylase (20,000 SKBU/g) along with protease, lipase, cellulase, lactase, and hemicellulase on complex food digestion was assessed using INFOGEST simulated static and semi-dynamic digestion models, with digestion progress monitored in terms of reducing sugars, free sugar profile, degree of hydrolysis, free amino acids, peptide pattern, and free fatty acids. These in vitro models provide a useful but limited proxy for human physiological digestion.
Evidence strength: The biochemical and mechanistic evidence for Taka-amylase's ability to hydrolyze starch is extremely well-characterized at the molecular level. Its use as a functional digestive enzyme when delivered orally is physiologically plausible and has a long empirical history. However, rigorous, placebo-controlled human clinical trials examining Taka-amylase as a standalone supplement for digestive outcomes — with defined populations, standardized dosing, and validated symptom endpoints — are sparse in the publicly available peer-reviewed literature. The evidence base for this specific preparation rests substantially on mechanistic reasoning, in vitro data, and historical clinical experience rather than modern high-quality randomized controlled trials.
Disruptions in enzyme production or activity — such as in exocrine pancreatic insufficiency, lactose intolerance, or congenital sucrase-isomaltase deficiency — impair nutrient absorption and lead to symptoms including diarrhea, bloating, flatulence, steatorrhea, and weight loss. Enzyme replacement in these conditions is well established as a clinical strategy; however, the standard of care for exocrine pancreatic insufficiency typically involves prescription porcine pancreatic enzyme replacement therapy (PERT), not fungal amylase supplements. No dedicated randomized controlled trials of Taka-amylase specifically for exocrine pancreatic insufficiency were identified in the peer-reviewed literature.
A substantial body of peer-reviewed research exists on Taka-amylase in the context of industrial starch processing, food biotechnology, and as a structural model enzyme. α-Amylase from Aspergillus oryzae is a staple of the enzyme industry and has been used for decades in medical and a variety of commercial processes. α-Amylase constitutes one of the most significant enzymes in industrial applications like textile, food, detergent, and bioclinical industries. This industrial evidence does not directly translate to clinical supplement evidence but confirms the enzyme's well-defined activity profile and safety record under food-processing conditions.
Taka-amylase A holds a unique place in the history of protein chemistry. Although enzymes extracted from animal organs were mainly studied in Europe and the U.S., they were difficult to obtain in Japan. In contrast, the enzymes produced by Japanese koji mold (Aspergillus oryzae) are generally more stable than animal-derived enzymes, which is an immense advantage for chemical studies. The availability and stability of Taka-amylase A made it the preferred subject for early crystallization studies of enzymes in Japan, contributing foundationally to the field of structural enzymology. Taka-amylase efficiently catalyzes the hydrolysis of starch and has high potential for industrial-scale production of glucose from various sources.
Taka-amylase acts primarily within the gastrointestinal tract, particularly in the oral cavity and small intestine. The primary function of amylases is to hydrolyze glycosidic bonds in starch molecules, converting complex carbohydrates into simpler sugars. Amylase enzymes are classified into three main categories: α-, β-, and γ-amylases, each exhibiting specificity for distinct segments of carbohydrate molecules. Supplements containing amylase are taken to support digestive comfort and efficiency, particularly after carbohydrate-heavy meals, and are often chosen by people prone to occasional bloating or digestive upset following starchy foods.
By converting complex starches into absorbable simpler sugars, amylase supplementation theoretically supports carbohydrate-derived energy metabolism and nutrient absorption. Up to 50% of energy intake can be derived from a single carbohydrate, starch. α-Amylases (EC 3.2.1.1) of salivary and pancreatic origin play a key role in the digestive process of starch and related physiological implications. The efficiency with which starch is converted to absorbable sugars has downstream effects on blood glucose response, gut microbiome substrate availability, and caloric recovery from starchy foods.
While not a direct application of Taka-amylase supplementation, the broader α-amylase enzyme class has well-established diagnostic significance. In clinical laboratories, the measurement of α-amylase, and specifically pancreatic α-amylase, in human serum and urine is a well-established and routinely used marker of acute pancreatitis — the main clinical application of this enzyme since the first description of its diagnostic value in 1929. Elevated serum amylase is used to diagnose pancreatic pathology. This diagnostic application is distinct from the supplemental use of Taka-amylase.
Supplemental amylase derived from Aspergillus oryzae is available as capsules, tablets, or blends in digestive enzyme formulas. Enzyme preparations are standardized by their catalytic activity rather than by absolute weight, using units such as SKB units (Sandstedt-Kneen-Blish), DU (dextrinizing units), FAU (fungal amylase units), or KNU (Kilo Novo Units) rather than by mass alone. This activity-based standardization means that dosages reported in milligrams in product labels reflect the mass of enzyme preparation, not the activity.
One in vitro study examined a multi-enzyme supplement formulation providing amylase at 20,000 SKBU/g, in combination with protease (13,000 PC/g), lipase (5 LU/g), cellulase (1,000 CMC/g), lactase (1,000 ALU/g), and hemicellulase (15,000 XU/g).
In an animal nutrition study using exogenous amylase, the enzyme was supplemented at the dosage recommended by the manufacturer (0.14 g/kg; 80 KNU/kg as fed). This study context is not directly applicable to human supplementation but reflects the enzyme activity units used in standardizing doses.
From historical product records, the Parke-Davis Taka-Diastase was provided as a powder, with dosing instructions from the early 20th century directing its use before meals for dyspeptic complaints. Contemporary dietary supplement products containing A. oryzae-derived amylase as part of a multi-enzyme blend vary widely in amylase activity per serving depending on the product formulation and intended use. No specific human clinical trials establishing an optimal dosage for Taka-amylase as a standalone supplement were identified in the peer-reviewed literature reviewed here.
Multiple independent evaluations from the European Food Safety Authority (EFSA) have assessed the safety of α-amylase derived from Aspergillus oryzae. Genotoxicity tests did not raise a safety concern. The systemic toxicity was assessed by means of a repeated-dose 90-day oral toxicity study in rats. The Panel identified a no observed adverse effect level (NOAEL) of 1,000 mg TOS/kg body weight per day, the highest dose tested. Based on the data provided, the Panel concluded that this food enzyme does not give rise to safety concerns under the intended conditions of use. A separate EFSA evaluation of a different A. oryzae strain found a NOAEL of 1,862 mg TOS/kg bw per day, the highest dose tested, which, when compared with the estimated dietary exposure, resulted in a margin of exposure of at least 13,896.
Aspergillus oryzae species have often been reported to be both non-toxigenic and non-pathogenic microorganisms. Genomic analysis has led some scholars to believe that the Japanese domesticated Aspergillus flavus that had mutated and ceased to produce toxic aflatoxins, giving rise to A. oryzae. While the two fungi share the same cluster of genes that encode for aflatoxin synthesis, this gene cluster is non-functional in A. oryzae.
The most clinically documented safety concern with A. oryzae α-amylase relates to its allergenicity. α-Amylase from A. oryzae is known as an occupational respiratory allergen associated with baker's asthma. The starch-degrading enzyme alpha-amylase from Aspergillus oryzae and soybean flour are examples of additives that, together with the cereal components, are responsible for sensitization and IgE-mediated symptoms in bakers and others exposed to baking flours. Sensitization to enzymes in bakeries is a common cause of occupational asthma and may also result in contact dermatitis. The prevalence of sensitization to alpha-amylase in symptomatic bakers is about 25%.
Iodine starch staining demonstrated that the component which was exclusively or predominantly bound by IgE antibodies of symptomatic bakers represents the active alpha-amylase. According to the International Union of Immunological Societies (IUIS) nomenclature, the term Asp o II is suggested for this important occupational allergen.
Notably, the risk of allergic reaction through oral ingestion (as in dietary supplementation) is substantially lower than the risk arising from inhalation of airborne enzyme dust. Several studies have shown that adults with occupational asthma caused by an enzyme (as described for α-amylase from A. oryzae) can ingest respiratory allergens without acquiring clinical symptoms of food allergy. Considering the wide use of α-amylases, only a low number of case reports have been described in the literature focused on allergic reactions upon oral exposure to α-amylases in individuals respiratorily sensitised to α-amylases. Nevertheless, similarity of the amino acid sequence to those of known allergens was searched and one match to a respiratory allergen was found (an amylase from another strain of A. oryzae). The Panel considered that, under the intended conditions of use, the risk of allergic sensitisation and elicitation reactions by dietary exposure cannot be excluded, but the likelihood is considered to be low.
Bread made from flour containing alpha-amylase from Aspergillus oryzae can trigger allergic reactions in sensitized subjects. Individuals with known hypersensitivity to Aspergillus species or to A. oryzae-derived enzymes represent a population for whom oral exposure should be considered cautiously.
Structurally, Taka-amylase is inhibited by acarbose, a prescription medication used to slow carbohydrate absorption for the management of type 2 diabetes. The three-dimensional structure of the Aspergillus oryzae alpha-amylase (TAKA-amylase), in complex with the inhibitor acarbose, has been determined by X-ray crystallography at a resolution of 1.98 Å. Given that acarbose functions precisely by inhibiting α-amylase activity in the gastrointestinal tract, co-administration of Taka-amylase supplements with acarbose or other α-glucosidase inhibitors would be expected to reduce or negate the supplemental effect, though this specific drug–supplement interaction has not been formally studied in clinical trials for Taka-amylase specifically.
As the enzyme is a protein, it is subject to inactivation by the acidic environment of the stomach to a varying degree. The extent of activity that survives gastric acid transit depends on the formulation — whether enteric-coated, taken with food (which buffers gastric pH), or taken as an unprotected capsule.
For products derived from fungal strains, the strains or resulting products are tested for the presence of secondary metabolites which could be of toxicological concern. These were found to be below the limits of detection, or the strain was not capable of producing them. Mycotoxin absence must be verified for each production strain, as the closely related A. flavus is aflatoxigenic, though A. oryzae itself has been documented to have a non-functional aflatoxin biosynthesis cluster.
The EFSA safety evaluations represent the most rigorous and systematically conducted assessments publicly available and cover genotoxicity, subchronic oral toxicity, and allergenicity assessment within the context of food processing use. These evaluations provide considerable reassurance regarding the safety of ingested A. oryzae-derived α-amylase. However, it must be noted that these evaluations are conducted primarily in the context of food enzyme use (where the enzyme is present at residual levels in processed foods), not in the context of concentrated dietary supplement use at the higher enzyme activities present in capsule or tablet formulations. Specific human safety trials of high-dose oral Taka-amylase as a dietary supplement over prolonged periods are not represented in the current accessible peer-reviewed literature.
Health conditions that Taka amylase may help support.
Body systems that Taka amylase may help support.
Go back